Skip to main content
. 2014 Jul 10;8(6):1095–1111. doi: 10.1016/j.molonc.2014.06.005

Figure 4.

Figure 4

Mechanisms of resistance to targeted therapies. Schematic summarising some of the described mechanisms of resistance to a selection of targeted therapies: Vemurafenib (BRAFV600E inhibitor), Imatinib (BCR‐ABL/cKIT/PDGFRA), EGFR tyrosine kinase inhibitors (e.g. gefitinib, erlotinib), EGFR targeted monoclonal antibodies (e.g. cetuximab, panitumumab), Crizotinib (ALK, ROS1 inhibitor). 1. (Heinrich et al., 2006; Liegl et al., 2008; Lim et al., 2008; Wardelmann et al., 2006) 2. (Debiec‐Rychter et al., 2005; Heinrich et al., 2006) 3. (Shah et al., 2002) 4. (Mahon et al., 2008) 5. (Gorre et al., 2001) 6. (Zhang et al., 2012) 7. (Inukai et al., 2006; Kosaka et al., 2006; Maheswaran et al., 2008) 8. (Turke et al., 2010) 9. (Nathanson et al., 2014) 10. (Amado et al., 2008; Bardelli et al., 2013; Diaz et al., 2012; Misale et al., 2012) 11. (Bardelli et al., 2013; Engelman et al., 2007) 12. (Sartore‐Bianchi et al., 2009) 13. (Katayama et al., 2012) 14. (Awad et al., 2013) 15. (Katayama et al., 2012) 16. (Choi et al., 2010; Katayama et al., 2012) 17. (Shi et al., 2014; Shi et al., 2012; Van Allen et al., 2014) 18. (Prahallad et al., 2012) 19. (Johannessen et al., 2010) 20. (Johannessen et al., 2013; Van Allen et al., 2014) 21. (Nazarian et al., 2010; Shi et al., 2014; Van Allen et al., 2014) 22. (Poulikakos et al., 2011; Shi et al., 2012) 23. (Shi et al., 2014; Van Allen et al., 2014) 24. (Turajlic et al., 2014).